Amneal Pharmaceuticals Inc (AMRX)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Amneal Pharmaceuticals Inc

Healthcare (1146)

908-947-3120

400 Crossing Boulevard, 3rd Floor, Bridgewater

@amnealpharma

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AMRX's Discussions on Twitter

Vergleichen Sie AMRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AMRX Amneal Pharmaceuticals Inc	9.715	3.06B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	143.43	63.05B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.80	43.33B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.175	40.43B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.11	22.97B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	433.02	19.90B	3.08B	1.24B	1.07B	25.61

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-06	Eingeleitet	Goldman	Buy
2025-02-24	Hochstufung	JP Morgan	Neutral → Overweight
2024-09-06	Hochstufung	JP Morgan	Underweight → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2021-03-08	Hochstufung	Goldman	Sell → Buy
2020-12-14	Hochstufung	Barclays	Equal Weight → Overweight
2020-12-14	Hochstufung	Guggenheim	Neutral → Buy
2020-07-27	Eingeleitet	Goldman	Sell
2020-05-12	Hochstufung	Guggenheim	Sell → Neutral
2019-12-12	Herabstufung	Raymond James	Outperform → Mkt Perform
2019-11-12	Herabstufung	JP Morgan	Neutral → Underweight
2019-11-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-07-22	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-07-11	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-07-08	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-21	Hochstufung	Raymond James	Mkt Perform → Strong Buy
2019-03-20	Eingeleitet	SunTrust	Buy
2019-03-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-12-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-10-16	Herabstufung	SunTrust	Buy → Hold
2018-08-13	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-07-23	Eingeleitet	Morgan Stanley	Overweight
2018-06-22	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Vergleichen Sie AMRX mit anderen Aktien

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten

What MACD and RSI say about Amneal Pharmaceuticals Inc.Oil Prices & Accurate Technical Buy Alerts - newser.com

Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - Sahm

What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com

Will Amneal Pharmaceuticals Inc. stock benefit from automationVolume Spike & Safe Capital Growth Tips - newser.com

Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - MSN

Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo

FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - Sahm

Will Amneal Pharmaceuticals Inc. see short term momentumTrade Analysis Report & Daily Volume Surge Signals - newser.com

Why Amneal Pharmaceuticals Inc. stock is considered a top pick2025 Market Outlook & Smart Swing Trading Alerts - newser.com

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga

Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com

When is the best time to exit Amneal Pharmaceuticals Inc.July 2025 Outlook & Weekly High Return Stock Opportunities - newser.com

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why - Yahoo Finance

Technical analysis overview for Amneal Pharmaceuticals Inc. stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com

A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst Upgrades - Yahoo Finance

Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings - MarketBeat

Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN

Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - sharewise.com

Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025? - Sahm

Amneal Pharmaceuticals (NASDAQ:AMRX) Increases 6.9% This Week, Taking Three-year Gains to 420% - 富途牛牛

Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - Nasdaq

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - Business Wire

Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stockJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com

Reversal indicators forming on Amneal Pharmaceuticals Inc. stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com

Is it time to cut losses on Amneal Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com

Using Python tools to backtest Amneal Pharmaceuticals Inc. strategies2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com

Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.Portfolio Risk Summary & High Win Rate Trade Tips - newser.com

How to read the order book for Amneal Pharmaceuticals Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryGap Down & Comprehensive Market Scan Insights - newser.com

Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo

Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com

Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com

What analysts say about Amneal Pharmaceuticals Inc stockGap Up/Gap Down Analysis & Free Take Advantage Of Momentum - earlytimes.in

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - sharewise.com

3 Lesser-Known Healthcare Names With Major Upside in Store - sharewise.com

3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com

Amneal Pharmaceuticals stock hits 52-week high at $10.36 By Investing.com - Investing.com Canada

Amneal Pharmaceuticals stock hits 52-week high at $10.36 - Investing.com

Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AMRX